Global Erythropoietin Stimulating Agents

Erythropoietin Stimulating Agents Comprehensive Study by Type (Erythropoietin, Epoetin alfa (Procrit, Epogen), Epoetin beta, Epoetin zeta (Silapo, Retacrit), Darbepoetin alfa, Methoxy polyethylene glycol-epoetin beta, Others), Application (Cancer, Hematology, Kidney Disorder, Renal Disorders, Anti-retroviral Treatment, Neural Diseases, Other), End-User (Hospital, Clinic, Others) Players and Region - Global Market Outlook to 2030

Erythropoietin Stimulating Agents Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Erythropoietin Stimulating Agents
The process of producing red blood cells is known as erythropoiesis. A hormone called erythropoietin, which is released by the kidneys and stimulates the bone marrow to make more blood cells, starts the process. Erythropoietin stimulating drugs are pharmaceuticals that work in the same way as erythropoietin to increase the number of blood cells in the body. Anemia can be caused by a range of medical illnesses, including cancer, blood disorders, neurological disorders, chronic renal disease, HIV, and others.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The market for Erythropoietin Stimulating Agents is fiercely competitive, with both worldwide and local players. Amgen, Thermos Fisher Scientific, Johnson & Johnson, F. Hoffmann-La Roche, and Pfizer Inc. are among the market's major participants. Several pharmaceutical companies are developing and producing ESAs after patents expire, and they are forming strategic alliances, such as acquisitions and collaborations, to expand their product portfolio globally. In addition, the report will include an in-depth analysis of major market strategies such as new product development/launch, mergers and acquisitions, partnerships, collaborations and joint ventures, research and development, and regional expansion. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Amgen Inc. (United States), F. Hoffmann La Roche Ltd (Switzerland), Thermo Fisher Scientific (United States), Johnson and Johnson (United States), Pfizer Inc. (United States), BioSidus (Argentina), Biocon (India), Celltrion (South Korea), Roche (Switzerland), Intas Pharmaceuticals (India) and Teva Pharmaceutical Industries (Israel) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Erythropoietin Stimulating Agents market by Type (Erythropoietin, Epoetin alfa (Procrit, Epogen), Epoetin beta, Epoetin zeta (Silapo, Retacrit), Darbepoetin alfa, Methoxy polyethylene glycol-epoetin beta and Others), Application (Cancer, Hematology, Kidney Disorder, Renal Disorders, Anti-retroviral Treatment, Neural Diseases and Other) and Region.



On the basis of geography, the market of Erythropoietin Stimulating Agents has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End-User, the sub-segment i.e. Hospital will boost the Erythropoietin Stimulating Agents market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Growth Drivers:
Increasing Incidences of Chronic Kidney Disease and Cancer and Increase in Production of Biosimilar Drugs Globally

Challenges:
Strict government regulation in the market

Restraints:
Side Effects Associated with Erythropoietin Stimulating Agents to Restrict the Market Growth

Opportunities:
Emerging Countries for Biosimilar Erythropoietin Stimulating Agents and Increasing Drug manufacturers in the developing countries

Market Leaders and their expansionary development strategies
In September 2019, The Darbepoetin Alfa BS Injection JCR, a long-acting erythropoiesis-stimulating agent, was approved in Japan by JCR Pharmaceuticals Co., Ltd. and Kissei Pharmaceutical Co., Ltd. The Phase III trial showed similar safety profiles and equivalency in efficacy and safety when compared to Darbepoetin alpha (innovator product)
In July 2020, PT Kalbe Genexine Biologics has started a Phase III clinical trial of Efepoetin Alfa for the treatment of anemia associated with chronic renal disease patients who are not on dialysis. and In Feb 2020, At Samsung Medical Center, a multicentre randomized study on the efficacy of Ferinject, an intravenous iron injection, in cancer patients with anemia has begun.


Key Target Audience
Industry Association, Downstream Vendors, Marketing & Consulting firms, Venture Capitalists, Government & Regulatory Bodies and Investors

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Erythropoietin
  • Epoetin alfa (Procrit, Epogen)
  • Epoetin beta
  • Epoetin zeta (Silapo, Retacrit)
  • Darbepoetin alfa
  • Methoxy polyethylene glycol-epoetin beta
  • Others
By Application
  • Cancer
  • Hematology
  • Kidney Disorder
  • Renal Disorders
  • Anti-retroviral Treatment
  • Neural Diseases
  • Other
By End-User
  • Hospital
  • Clinic
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Incidences of Chronic Kidney Disease and Cancer
      • 3.2.2. Increase in Production of Biosimilar Drugs Globally
    • 3.3. Market Challenges
      • 3.3.1. Strict government regulation in the market
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Erythropoietin Stimulating Agents, by Type, Application, End-User and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Erythropoietin Stimulating Agents (Value)
      • 5.2.1. Global Erythropoietin Stimulating Agents by: Type (Value)
        • 5.2.1.1. Erythropoietin
        • 5.2.1.2. Epoetin alfa (Procrit, Epogen)
        • 5.2.1.3. Epoetin beta
        • 5.2.1.4. Epoetin zeta (Silapo, Retacrit)
        • 5.2.1.5. Darbepoetin alfa
        • 5.2.1.6. Methoxy polyethylene glycol-epoetin beta
        • 5.2.1.7. Others
      • 5.2.2. Global Erythropoietin Stimulating Agents by: Application (Value)
        • 5.2.2.1. Cancer
        • 5.2.2.2. Hematology
        • 5.2.2.3. Kidney Disorder
        • 5.2.2.4. Renal Disorders
        • 5.2.2.5. Anti-retroviral Treatment
        • 5.2.2.6. Neural Diseases
        • 5.2.2.7. Other
      • 5.2.3. Global Erythropoietin Stimulating Agents by: End-User (Value)
        • 5.2.3.1. Hospital
        • 5.2.3.2. Clinic
        • 5.2.3.3. Others
      • 5.2.4. Global Erythropoietin Stimulating Agents Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Erythropoietin Stimulating Agents (Price)
      • 5.3.1. Global Erythropoietin Stimulating Agents by: Type (Price)
  • 6. Erythropoietin Stimulating Agents: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Amgen Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. F. Hoffmann La Roche Ltd (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Thermo Fisher Scientific (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Johnson and Johnson (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. BioSidus (Argentina)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Biocon (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Celltrion (South Korea)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Roche (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Intas Pharmaceuticals (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Teva Pharmaceutical Industries (Israel)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Erythropoietin Stimulating Agents Sale, by Type, Application, End-User and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Erythropoietin Stimulating Agents (Value)
      • 7.2.1. Global Erythropoietin Stimulating Agents by: Type (Value)
        • 7.2.1.1. Erythropoietin
        • 7.2.1.2. Epoetin alfa (Procrit, Epogen)
        • 7.2.1.3. Epoetin beta
        • 7.2.1.4. Epoetin zeta (Silapo, Retacrit)
        • 7.2.1.5. Darbepoetin alfa
        • 7.2.1.6. Methoxy polyethylene glycol-epoetin beta
        • 7.2.1.7. Others
      • 7.2.2. Global Erythropoietin Stimulating Agents by: Application (Value)
        • 7.2.2.1. Cancer
        • 7.2.2.2. Hematology
        • 7.2.2.3. Kidney Disorder
        • 7.2.2.4. Renal Disorders
        • 7.2.2.5. Anti-retroviral Treatment
        • 7.2.2.6. Neural Diseases
        • 7.2.2.7. Other
      • 7.2.3. Global Erythropoietin Stimulating Agents by: End-User (Value)
        • 7.2.3.1. Hospital
        • 7.2.3.2. Clinic
        • 7.2.3.3. Others
      • 7.2.4. Global Erythropoietin Stimulating Agents Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Erythropoietin Stimulating Agents (Price)
      • 7.3.1. Global Erythropoietin Stimulating Agents by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Erythropoietin Stimulating Agents: by Type(USD Million)
  • Table 2. Erythropoietin Stimulating Agents Erythropoietin , by Region USD Million (2018-2023)
  • Table 3. Erythropoietin Stimulating Agents Epoetin alfa (Procrit, Epogen) , by Region USD Million (2018-2023)
  • Table 4. Erythropoietin Stimulating Agents Epoetin beta , by Region USD Million (2018-2023)
  • Table 5. Erythropoietin Stimulating Agents Epoetin zeta (Silapo, Retacrit) , by Region USD Million (2018-2023)
  • Table 6. Erythropoietin Stimulating Agents Darbepoetin alfa , by Region USD Million (2018-2023)
  • Table 7. Erythropoietin Stimulating Agents Methoxy polyethylene glycol-epoetin beta , by Region USD Million (2018-2023)
  • Table 8. Erythropoietin Stimulating Agents Others , by Region USD Million (2018-2023)
  • Table 9. Erythropoietin Stimulating Agents: by Application(USD Million)
  • Table 10. Erythropoietin Stimulating Agents Cancer , by Region USD Million (2018-2023)
  • Table 11. Erythropoietin Stimulating Agents Hematology , by Region USD Million (2018-2023)
  • Table 12. Erythropoietin Stimulating Agents Kidney Disorder , by Region USD Million (2018-2023)
  • Table 13. Erythropoietin Stimulating Agents Renal Disorders , by Region USD Million (2018-2023)
  • Table 14. Erythropoietin Stimulating Agents Anti-retroviral Treatment , by Region USD Million (2018-2023)
  • Table 15. Erythropoietin Stimulating Agents Neural Diseases , by Region USD Million (2018-2023)
  • Table 16. Erythropoietin Stimulating Agents Other , by Region USD Million (2018-2023)
  • Table 17. Erythropoietin Stimulating Agents: by End-User(USD Million)
  • Table 18. Erythropoietin Stimulating Agents Hospital , by Region USD Million (2018-2023)
  • Table 19. Erythropoietin Stimulating Agents Clinic , by Region USD Million (2018-2023)
  • Table 20. Erythropoietin Stimulating Agents Others , by Region USD Million (2018-2023)
  • Table 21. South America Erythropoietin Stimulating Agents, by Country USD Million (2018-2023)
  • Table 22. South America Erythropoietin Stimulating Agents, by Type USD Million (2018-2023)
  • Table 23. South America Erythropoietin Stimulating Agents, by Application USD Million (2018-2023)
  • Table 24. South America Erythropoietin Stimulating Agents, by End-User USD Million (2018-2023)
  • Table 25. Brazil Erythropoietin Stimulating Agents, by Type USD Million (2018-2023)
  • Table 26. Brazil Erythropoietin Stimulating Agents, by Application USD Million (2018-2023)
  • Table 27. Brazil Erythropoietin Stimulating Agents, by End-User USD Million (2018-2023)
  • Table 28. Argentina Erythropoietin Stimulating Agents, by Type USD Million (2018-2023)
  • Table 29. Argentina Erythropoietin Stimulating Agents, by Application USD Million (2018-2023)
  • Table 30. Argentina Erythropoietin Stimulating Agents, by End-User USD Million (2018-2023)
  • Table 31. Rest of South America Erythropoietin Stimulating Agents, by Type USD Million (2018-2023)
  • Table 32. Rest of South America Erythropoietin Stimulating Agents, by Application USD Million (2018-2023)
  • Table 33. Rest of South America Erythropoietin Stimulating Agents, by End-User USD Million (2018-2023)
  • Table 34. Asia Pacific Erythropoietin Stimulating Agents, by Country USD Million (2018-2023)
  • Table 35. Asia Pacific Erythropoietin Stimulating Agents, by Type USD Million (2018-2023)
  • Table 36. Asia Pacific Erythropoietin Stimulating Agents, by Application USD Million (2018-2023)
  • Table 37. Asia Pacific Erythropoietin Stimulating Agents, by End-User USD Million (2018-2023)
  • Table 38. China Erythropoietin Stimulating Agents, by Type USD Million (2018-2023)
  • Table 39. China Erythropoietin Stimulating Agents, by Application USD Million (2018-2023)
  • Table 40. China Erythropoietin Stimulating Agents, by End-User USD Million (2018-2023)
  • Table 41. Japan Erythropoietin Stimulating Agents, by Type USD Million (2018-2023)
  • Table 42. Japan Erythropoietin Stimulating Agents, by Application USD Million (2018-2023)
  • Table 43. Japan Erythropoietin Stimulating Agents, by End-User USD Million (2018-2023)
  • Table 44. India Erythropoietin Stimulating Agents, by Type USD Million (2018-2023)
  • Table 45. India Erythropoietin Stimulating Agents, by Application USD Million (2018-2023)
  • Table 46. India Erythropoietin Stimulating Agents, by End-User USD Million (2018-2023)
  • Table 47. South Korea Erythropoietin Stimulating Agents, by Type USD Million (2018-2023)
  • Table 48. South Korea Erythropoietin Stimulating Agents, by Application USD Million (2018-2023)
  • Table 49. South Korea Erythropoietin Stimulating Agents, by End-User USD Million (2018-2023)
  • Table 50. Taiwan Erythropoietin Stimulating Agents, by Type USD Million (2018-2023)
  • Table 51. Taiwan Erythropoietin Stimulating Agents, by Application USD Million (2018-2023)
  • Table 52. Taiwan Erythropoietin Stimulating Agents, by End-User USD Million (2018-2023)
  • Table 53. Australia Erythropoietin Stimulating Agents, by Type USD Million (2018-2023)
  • Table 54. Australia Erythropoietin Stimulating Agents, by Application USD Million (2018-2023)
  • Table 55. Australia Erythropoietin Stimulating Agents, by End-User USD Million (2018-2023)
  • Table 56. Rest of Asia-Pacific Erythropoietin Stimulating Agents, by Type USD Million (2018-2023)
  • Table 57. Rest of Asia-Pacific Erythropoietin Stimulating Agents, by Application USD Million (2018-2023)
  • Table 58. Rest of Asia-Pacific Erythropoietin Stimulating Agents, by End-User USD Million (2018-2023)
  • Table 59. Europe Erythropoietin Stimulating Agents, by Country USD Million (2018-2023)
  • Table 60. Europe Erythropoietin Stimulating Agents, by Type USD Million (2018-2023)
  • Table 61. Europe Erythropoietin Stimulating Agents, by Application USD Million (2018-2023)
  • Table 62. Europe Erythropoietin Stimulating Agents, by End-User USD Million (2018-2023)
  • Table 63. Germany Erythropoietin Stimulating Agents, by Type USD Million (2018-2023)
  • Table 64. Germany Erythropoietin Stimulating Agents, by Application USD Million (2018-2023)
  • Table 65. Germany Erythropoietin Stimulating Agents, by End-User USD Million (2018-2023)
  • Table 66. France Erythropoietin Stimulating Agents, by Type USD Million (2018-2023)
  • Table 67. France Erythropoietin Stimulating Agents, by Application USD Million (2018-2023)
  • Table 68. France Erythropoietin Stimulating Agents, by End-User USD Million (2018-2023)
  • Table 69. Italy Erythropoietin Stimulating Agents, by Type USD Million (2018-2023)
  • Table 70. Italy Erythropoietin Stimulating Agents, by Application USD Million (2018-2023)
  • Table 71. Italy Erythropoietin Stimulating Agents, by End-User USD Million (2018-2023)
  • Table 72. United Kingdom Erythropoietin Stimulating Agents, by Type USD Million (2018-2023)
  • Table 73. United Kingdom Erythropoietin Stimulating Agents, by Application USD Million (2018-2023)
  • Table 74. United Kingdom Erythropoietin Stimulating Agents, by End-User USD Million (2018-2023)
  • Table 75. Netherlands Erythropoietin Stimulating Agents, by Type USD Million (2018-2023)
  • Table 76. Netherlands Erythropoietin Stimulating Agents, by Application USD Million (2018-2023)
  • Table 77. Netherlands Erythropoietin Stimulating Agents, by End-User USD Million (2018-2023)
  • Table 78. Rest of Europe Erythropoietin Stimulating Agents, by Type USD Million (2018-2023)
  • Table 79. Rest of Europe Erythropoietin Stimulating Agents, by Application USD Million (2018-2023)
  • Table 80. Rest of Europe Erythropoietin Stimulating Agents, by End-User USD Million (2018-2023)
  • Table 81. MEA Erythropoietin Stimulating Agents, by Country USD Million (2018-2023)
  • Table 82. MEA Erythropoietin Stimulating Agents, by Type USD Million (2018-2023)
  • Table 83. MEA Erythropoietin Stimulating Agents, by Application USD Million (2018-2023)
  • Table 84. MEA Erythropoietin Stimulating Agents, by End-User USD Million (2018-2023)
  • Table 85. Middle East Erythropoietin Stimulating Agents, by Type USD Million (2018-2023)
  • Table 86. Middle East Erythropoietin Stimulating Agents, by Application USD Million (2018-2023)
  • Table 87. Middle East Erythropoietin Stimulating Agents, by End-User USD Million (2018-2023)
  • Table 88. Africa Erythropoietin Stimulating Agents, by Type USD Million (2018-2023)
  • Table 89. Africa Erythropoietin Stimulating Agents, by Application USD Million (2018-2023)
  • Table 90. Africa Erythropoietin Stimulating Agents, by End-User USD Million (2018-2023)
  • Table 91. North America Erythropoietin Stimulating Agents, by Country USD Million (2018-2023)
  • Table 92. North America Erythropoietin Stimulating Agents, by Type USD Million (2018-2023)
  • Table 93. North America Erythropoietin Stimulating Agents, by Application USD Million (2018-2023)
  • Table 94. North America Erythropoietin Stimulating Agents, by End-User USD Million (2018-2023)
  • Table 95. United States Erythropoietin Stimulating Agents, by Type USD Million (2018-2023)
  • Table 96. United States Erythropoietin Stimulating Agents, by Application USD Million (2018-2023)
  • Table 97. United States Erythropoietin Stimulating Agents, by End-User USD Million (2018-2023)
  • Table 98. Canada Erythropoietin Stimulating Agents, by Type USD Million (2018-2023)
  • Table 99. Canada Erythropoietin Stimulating Agents, by Application USD Million (2018-2023)
  • Table 100. Canada Erythropoietin Stimulating Agents, by End-User USD Million (2018-2023)
  • Table 101. Mexico Erythropoietin Stimulating Agents, by Type USD Million (2018-2023)
  • Table 102. Mexico Erythropoietin Stimulating Agents, by Application USD Million (2018-2023)
  • Table 103. Mexico Erythropoietin Stimulating Agents, by End-User USD Million (2018-2023)
  • Table 104. Erythropoietin Stimulating Agents: by Type(USD/Units)
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Company Basic Information, Sales Area and Its Competitors
  • Table 114. Company Basic Information, Sales Area and Its Competitors
  • Table 115. Company Basic Information, Sales Area and Its Competitors
  • Table 116. Erythropoietin Stimulating Agents: by Type(USD Million)
  • Table 117. Erythropoietin Stimulating Agents Erythropoietin , by Region USD Million (2025-2030)
  • Table 118. Erythropoietin Stimulating Agents Epoetin alfa (Procrit, Epogen) , by Region USD Million (2025-2030)
  • Table 119. Erythropoietin Stimulating Agents Epoetin beta , by Region USD Million (2025-2030)
  • Table 120. Erythropoietin Stimulating Agents Epoetin zeta (Silapo, Retacrit) , by Region USD Million (2025-2030)
  • Table 121. Erythropoietin Stimulating Agents Darbepoetin alfa , by Region USD Million (2025-2030)
  • Table 122. Erythropoietin Stimulating Agents Methoxy polyethylene glycol-epoetin beta , by Region USD Million (2025-2030)
  • Table 123. Erythropoietin Stimulating Agents Others , by Region USD Million (2025-2030)
  • Table 124. Erythropoietin Stimulating Agents: by Application(USD Million)
  • Table 125. Erythropoietin Stimulating Agents Cancer , by Region USD Million (2025-2030)
  • Table 126. Erythropoietin Stimulating Agents Hematology , by Region USD Million (2025-2030)
  • Table 127. Erythropoietin Stimulating Agents Kidney Disorder , by Region USD Million (2025-2030)
  • Table 128. Erythropoietin Stimulating Agents Renal Disorders , by Region USD Million (2025-2030)
  • Table 129. Erythropoietin Stimulating Agents Anti-retroviral Treatment , by Region USD Million (2025-2030)
  • Table 130. Erythropoietin Stimulating Agents Neural Diseases , by Region USD Million (2025-2030)
  • Table 131. Erythropoietin Stimulating Agents Other , by Region USD Million (2025-2030)
  • Table 132. Erythropoietin Stimulating Agents: by End-User(USD Million)
  • Table 133. Erythropoietin Stimulating Agents Hospital , by Region USD Million (2025-2030)
  • Table 134. Erythropoietin Stimulating Agents Clinic , by Region USD Million (2025-2030)
  • Table 135. Erythropoietin Stimulating Agents Others , by Region USD Million (2025-2030)
  • Table 136. South America Erythropoietin Stimulating Agents, by Country USD Million (2025-2030)
  • Table 137. South America Erythropoietin Stimulating Agents, by Type USD Million (2025-2030)
  • Table 138. South America Erythropoietin Stimulating Agents, by Application USD Million (2025-2030)
  • Table 139. South America Erythropoietin Stimulating Agents, by End-User USD Million (2025-2030)
  • Table 140. Brazil Erythropoietin Stimulating Agents, by Type USD Million (2025-2030)
  • Table 141. Brazil Erythropoietin Stimulating Agents, by Application USD Million (2025-2030)
  • Table 142. Brazil Erythropoietin Stimulating Agents, by End-User USD Million (2025-2030)
  • Table 143. Argentina Erythropoietin Stimulating Agents, by Type USD Million (2025-2030)
  • Table 144. Argentina Erythropoietin Stimulating Agents, by Application USD Million (2025-2030)
  • Table 145. Argentina Erythropoietin Stimulating Agents, by End-User USD Million (2025-2030)
  • Table 146. Rest of South America Erythropoietin Stimulating Agents, by Type USD Million (2025-2030)
  • Table 147. Rest of South America Erythropoietin Stimulating Agents, by Application USD Million (2025-2030)
  • Table 148. Rest of South America Erythropoietin Stimulating Agents, by End-User USD Million (2025-2030)
  • Table 149. Asia Pacific Erythropoietin Stimulating Agents, by Country USD Million (2025-2030)
  • Table 150. Asia Pacific Erythropoietin Stimulating Agents, by Type USD Million (2025-2030)
  • Table 151. Asia Pacific Erythropoietin Stimulating Agents, by Application USD Million (2025-2030)
  • Table 152. Asia Pacific Erythropoietin Stimulating Agents, by End-User USD Million (2025-2030)
  • Table 153. China Erythropoietin Stimulating Agents, by Type USD Million (2025-2030)
  • Table 154. China Erythropoietin Stimulating Agents, by Application USD Million (2025-2030)
  • Table 155. China Erythropoietin Stimulating Agents, by End-User USD Million (2025-2030)
  • Table 156. Japan Erythropoietin Stimulating Agents, by Type USD Million (2025-2030)
  • Table 157. Japan Erythropoietin Stimulating Agents, by Application USD Million (2025-2030)
  • Table 158. Japan Erythropoietin Stimulating Agents, by End-User USD Million (2025-2030)
  • Table 159. India Erythropoietin Stimulating Agents, by Type USD Million (2025-2030)
  • Table 160. India Erythropoietin Stimulating Agents, by Application USD Million (2025-2030)
  • Table 161. India Erythropoietin Stimulating Agents, by End-User USD Million (2025-2030)
  • Table 162. South Korea Erythropoietin Stimulating Agents, by Type USD Million (2025-2030)
  • Table 163. South Korea Erythropoietin Stimulating Agents, by Application USD Million (2025-2030)
  • Table 164. South Korea Erythropoietin Stimulating Agents, by End-User USD Million (2025-2030)
  • Table 165. Taiwan Erythropoietin Stimulating Agents, by Type USD Million (2025-2030)
  • Table 166. Taiwan Erythropoietin Stimulating Agents, by Application USD Million (2025-2030)
  • Table 167. Taiwan Erythropoietin Stimulating Agents, by End-User USD Million (2025-2030)
  • Table 168. Australia Erythropoietin Stimulating Agents, by Type USD Million (2025-2030)
  • Table 169. Australia Erythropoietin Stimulating Agents, by Application USD Million (2025-2030)
  • Table 170. Australia Erythropoietin Stimulating Agents, by End-User USD Million (2025-2030)
  • Table 171. Rest of Asia-Pacific Erythropoietin Stimulating Agents, by Type USD Million (2025-2030)
  • Table 172. Rest of Asia-Pacific Erythropoietin Stimulating Agents, by Application USD Million (2025-2030)
  • Table 173. Rest of Asia-Pacific Erythropoietin Stimulating Agents, by End-User USD Million (2025-2030)
  • Table 174. Europe Erythropoietin Stimulating Agents, by Country USD Million (2025-2030)
  • Table 175. Europe Erythropoietin Stimulating Agents, by Type USD Million (2025-2030)
  • Table 176. Europe Erythropoietin Stimulating Agents, by Application USD Million (2025-2030)
  • Table 177. Europe Erythropoietin Stimulating Agents, by End-User USD Million (2025-2030)
  • Table 178. Germany Erythropoietin Stimulating Agents, by Type USD Million (2025-2030)
  • Table 179. Germany Erythropoietin Stimulating Agents, by Application USD Million (2025-2030)
  • Table 180. Germany Erythropoietin Stimulating Agents, by End-User USD Million (2025-2030)
  • Table 181. France Erythropoietin Stimulating Agents, by Type USD Million (2025-2030)
  • Table 182. France Erythropoietin Stimulating Agents, by Application USD Million (2025-2030)
  • Table 183. France Erythropoietin Stimulating Agents, by End-User USD Million (2025-2030)
  • Table 184. Italy Erythropoietin Stimulating Agents, by Type USD Million (2025-2030)
  • Table 185. Italy Erythropoietin Stimulating Agents, by Application USD Million (2025-2030)
  • Table 186. Italy Erythropoietin Stimulating Agents, by End-User USD Million (2025-2030)
  • Table 187. United Kingdom Erythropoietin Stimulating Agents, by Type USD Million (2025-2030)
  • Table 188. United Kingdom Erythropoietin Stimulating Agents, by Application USD Million (2025-2030)
  • Table 189. United Kingdom Erythropoietin Stimulating Agents, by End-User USD Million (2025-2030)
  • Table 190. Netherlands Erythropoietin Stimulating Agents, by Type USD Million (2025-2030)
  • Table 191. Netherlands Erythropoietin Stimulating Agents, by Application USD Million (2025-2030)
  • Table 192. Netherlands Erythropoietin Stimulating Agents, by End-User USD Million (2025-2030)
  • Table 193. Rest of Europe Erythropoietin Stimulating Agents, by Type USD Million (2025-2030)
  • Table 194. Rest of Europe Erythropoietin Stimulating Agents, by Application USD Million (2025-2030)
  • Table 195. Rest of Europe Erythropoietin Stimulating Agents, by End-User USD Million (2025-2030)
  • Table 196. MEA Erythropoietin Stimulating Agents, by Country USD Million (2025-2030)
  • Table 197. MEA Erythropoietin Stimulating Agents, by Type USD Million (2025-2030)
  • Table 198. MEA Erythropoietin Stimulating Agents, by Application USD Million (2025-2030)
  • Table 199. MEA Erythropoietin Stimulating Agents, by End-User USD Million (2025-2030)
  • Table 200. Middle East Erythropoietin Stimulating Agents, by Type USD Million (2025-2030)
  • Table 201. Middle East Erythropoietin Stimulating Agents, by Application USD Million (2025-2030)
  • Table 202. Middle East Erythropoietin Stimulating Agents, by End-User USD Million (2025-2030)
  • Table 203. Africa Erythropoietin Stimulating Agents, by Type USD Million (2025-2030)
  • Table 204. Africa Erythropoietin Stimulating Agents, by Application USD Million (2025-2030)
  • Table 205. Africa Erythropoietin Stimulating Agents, by End-User USD Million (2025-2030)
  • Table 206. North America Erythropoietin Stimulating Agents, by Country USD Million (2025-2030)
  • Table 207. North America Erythropoietin Stimulating Agents, by Type USD Million (2025-2030)
  • Table 208. North America Erythropoietin Stimulating Agents, by Application USD Million (2025-2030)
  • Table 209. North America Erythropoietin Stimulating Agents, by End-User USD Million (2025-2030)
  • Table 210. United States Erythropoietin Stimulating Agents, by Type USD Million (2025-2030)
  • Table 211. United States Erythropoietin Stimulating Agents, by Application USD Million (2025-2030)
  • Table 212. United States Erythropoietin Stimulating Agents, by End-User USD Million (2025-2030)
  • Table 213. Canada Erythropoietin Stimulating Agents, by Type USD Million (2025-2030)
  • Table 214. Canada Erythropoietin Stimulating Agents, by Application USD Million (2025-2030)
  • Table 215. Canada Erythropoietin Stimulating Agents, by End-User USD Million (2025-2030)
  • Table 216. Mexico Erythropoietin Stimulating Agents, by Type USD Million (2025-2030)
  • Table 217. Mexico Erythropoietin Stimulating Agents, by Application USD Million (2025-2030)
  • Table 218. Mexico Erythropoietin Stimulating Agents, by End-User USD Million (2025-2030)
  • Table 219. Erythropoietin Stimulating Agents: by Type(USD/Units)
  • Table 220. Research Programs/Design for This Report
  • Table 221. Key Data Information from Secondary Sources
  • Table 222. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Erythropoietin Stimulating Agents: by Type USD Million (2018-2023)
  • Figure 5. Global Erythropoietin Stimulating Agents: by Application USD Million (2018-2023)
  • Figure 6. Global Erythropoietin Stimulating Agents: by End-User USD Million (2018-2023)
  • Figure 7. South America Erythropoietin Stimulating Agents Share (%), by Country
  • Figure 8. Asia Pacific Erythropoietin Stimulating Agents Share (%), by Country
  • Figure 9. Europe Erythropoietin Stimulating Agents Share (%), by Country
  • Figure 10. MEA Erythropoietin Stimulating Agents Share (%), by Country
  • Figure 11. North America Erythropoietin Stimulating Agents Share (%), by Country
  • Figure 12. Global Erythropoietin Stimulating Agents: by Type USD/Units (2018-2023)
  • Figure 13. Global Erythropoietin Stimulating Agents share by Players 2023 (%)
  • Figure 14. Global Erythropoietin Stimulating Agents share by Players (Top 3) 2023(%)
  • Figure 15. Global Erythropoietin Stimulating Agents share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Amgen Inc. (United States) Revenue: by Geography 2023
  • Figure 19. F. Hoffmann La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 20. F. Hoffmann La Roche Ltd (Switzerland) Revenue: by Geography 2023
  • Figure 21. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 22. Thermo Fisher Scientific (United States) Revenue: by Geography 2023
  • Figure 23. Johnson and Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 24. Johnson and Johnson (United States) Revenue: by Geography 2023
  • Figure 25. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 27. BioSidus (Argentina) Revenue, Net Income and Gross profit
  • Figure 28. BioSidus (Argentina) Revenue: by Geography 2023
  • Figure 29. Biocon (India) Revenue, Net Income and Gross profit
  • Figure 30. Biocon (India) Revenue: by Geography 2023
  • Figure 31. Celltrion (South Korea) Revenue, Net Income and Gross profit
  • Figure 32. Celltrion (South Korea) Revenue: by Geography 2023
  • Figure 33. Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. Roche (Switzerland) Revenue: by Geography 2023
  • Figure 35. Intas Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 36. Intas Pharmaceuticals (India) Revenue: by Geography 2023
  • Figure 37. Teva Pharmaceutical Industries (Israel) Revenue, Net Income and Gross profit
  • Figure 38. Teva Pharmaceutical Industries (Israel) Revenue: by Geography 2023
  • Figure 39. Global Erythropoietin Stimulating Agents: by Type USD Million (2025-2030)
  • Figure 40. Global Erythropoietin Stimulating Agents: by Application USD Million (2025-2030)
  • Figure 41. Global Erythropoietin Stimulating Agents: by End-User USD Million (2025-2030)
  • Figure 42. South America Erythropoietin Stimulating Agents Share (%), by Country
  • Figure 43. Asia Pacific Erythropoietin Stimulating Agents Share (%), by Country
  • Figure 44. Europe Erythropoietin Stimulating Agents Share (%), by Country
  • Figure 45. MEA Erythropoietin Stimulating Agents Share (%), by Country
  • Figure 46. North America Erythropoietin Stimulating Agents Share (%), by Country
  • Figure 47. Global Erythropoietin Stimulating Agents: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Amgen Inc. (United States)
  • F. Hoffmann La Roche Ltd (Switzerland)
  • Thermo Fisher Scientific (United States)
  • Johnson and Johnson (United States)
  • Pfizer Inc. (United States)
  • BioSidus (Argentina)
  • Biocon (India)
  • Celltrion (South Korea)
  • Roche (Switzerland)
  • Intas Pharmaceuticals (India)
  • Teva Pharmaceutical Industries (Israel)
Select User Access Type

Key Highlights of Report


Jan 2024 243 Pages 90 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Erythropoietin Stimulating Agents Quantitative research analysis
Global Erythropoietin Stimulating Agents Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Amgen Inc. (United States), F. Hoffmann La Roche Ltd (Switzerland), Thermo Fisher Scientific (United States), Johnson and Johnson (United States), Pfizer Inc. (United States), BioSidus (Argentina), Biocon (India), Celltrion (South Korea), Roche (Switzerland), Intas Pharmaceuticals (India) and Teva Pharmaceutical Industries (Israel) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"" is seen as one of major influencing trends for Erythropoietin Stimulating Agents Market during projected period 2023-2030.
The Erythropoietin Stimulating Agents market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Erythropoietin Stimulating Agents Report?

Have a Query? Click Here

Other Related Reports

Coronavirus Testing Kits Comprehensive Study by Type (Immunoassay test strips, RT PCR Assay kits, Others), Application (Infectious Diseases, Respiratory Diseases), Test (Molecular, Serological), Use ...
$ 3650
Diagnostic Specialty Enzymes Comprehensive Study by Type (Protease, Carbohydrase, Lipase, Polymerase and Nuclease, Others), Application (Food and Beverages, Household Care, Bioenergy, Pharmaceutical ...
$ 3650
Swab and Viral Transport Medium Comprehensive Study by Type (Nasopharyngeal, Oropharyngeal, Others), Application (Diagnosis of Viral Infections, Preclinical Testing, Others), End-User (Microbiology L...
$ 3650
Doxycycline Comprehensive Study by Type (Capsules, Tablets, Syrup, Oral Suspension, Injection Powder, Periodontal Extended Release Liquid), Application (Ureaplasma, Typhus, Chancroid, Brucellosis, An...
$ 3650
Disposable Medical Pulp Products Comprehensive Study by Type (Detergent Proof Wash Bowl, General Purpose Bowl, Kidney Dish, Commode Pan Liner, CS Receiver, Urinals), Application (Surgeries, Hospitals...
$ 3600
Dental Desensitizer Comprehensive Study by Type (Fluoride-containing Dental Desensitizer, Fluoride-free Dental Desensitizer), Application (Hospitals, Clinics, Pharmacy, Others), Distribution Channel ...
$ 3650